Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2. (Q37827451)

23 August 2017

1 reference

title

Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2. (English)

1 reference

23 August 2017

0 references

1 reference

1 reference

Jennifer Spratlin

1

1 reference

23 August 2017

publication date

1 April 2011

1 reference

23 August 2017

published in

Current Oncology Reports

1 reference

23 August 2017

volume

13

1 reference

23 August 2017

issue

2

1 reference

23 August 2017

page(s)

97-102

1 reference

Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0149-5

Angiogenesis in cancer, vascular, rheumatoid and other disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0149-5

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0149-5

VEGFs, receptors and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0149-5

Receptor-selective variants of human vascular endothelial growth factor. Generation and characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0149-5

Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0149-5

Vascular endothelial growth factor is a secreted angiogenic mitogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0149-5

Wingless capture by Frizzled and Frizzled2 in Drosophila embryos

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0149-5

Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0149-5

Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0149-5

Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0149-5

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0149-5

Regression of established tumors and metastases by potent vascular endothelial growth factor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0149-5

Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0149-5

Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0149-5

Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0149-5

Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0149-5

Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0149-5

Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0149-5

The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients

21 January 2018

1 reference

12 December 2020

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

1 reference

12 December 2020

Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.

1 reference

12 December 2020

A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma

1 reference

12 December 2020

Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

12 December 2020

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

1 reference

12 December 2020

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

1 reference

12 December 2020

Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model

1 reference

12 December 2020

Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms

1 reference

12 December 2020

Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors

1 reference

12 December 2020

A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period

1 reference

12 December 2020

Vascular endothelial growth factor (VEGF) and its receptors

1 reference

12 December 2020

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

1 reference

12 December 2020

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

1 reference

12 December 2020

10.1007/S11912-010-0149-5

Identifiers

DOI

1 reference

23 August 2017

1 reference